CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Down 17.0% in April

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) saw a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 314,100 shares, a decline of 17.0% from the March 31st total of 378,400 shares. Currently, 2.1% of the company’s shares are short sold. Based on an average daily trading volume, of 1,420,000 shares, the short-interest ratio is presently 0.2 days.

An institutional investor recently bought a new position in CNS Pharmaceuticals stock. Warberg Asset Management LLC bought a new position in shares of CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 14,000 shares of the company’s stock, valued at approximately $25,000. Warberg Asset Management LLC owned approximately 0.06% of CNS Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 0.58% of the company’s stock.

CNSP stock traded down $0.09 during mid-day trading on Tuesday, hitting $1.91. 1,445 shares of the company were exchanged, compared to its average volume of 1,328,606. CNS Pharmaceuticals has a 12-month low of $1.59 and a 12-month high of $4.46. The firm has a market capitalization of $48.32 million, a P/E ratio of -7.14 and a beta of 2.47. The business has a fifty day simple moving average of $2.30 and a 200-day simple moving average of $2.29.

CNS Pharmaceuticals (NASDAQ:CNSP) last posted its earnings results on Friday, February 12th. The company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.09). As a group, equities analysts expect that CNS Pharmaceuticals will post -0.52 EPS for the current fiscal year.

A number of brokerages have issued reports on CNSP. Brookline Capital Management initiated coverage on CNS Pharmaceuticals in a research note on Tuesday, February 2nd. They issued a “buy” rating and a $10.00 target price for the company. Zacks Investment Research lowered shares of CNS Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, February 17th.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.

Featured Article: Net Asset Value

Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with's FREE daily email newsletter.